Cargando…

Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes

Soft tissue sarcomas (STS) are rare tumors; they do not even equate to 1% of all malignant tumor cases. One-fifth of all STS occur in the upper extremities, where epithelioid sarcoma, synovial sarcoma, clear cell sarcoma and malignant fibrohistiocytoma are the most frequent subtypes. Surgical resect...

Descripción completa

Detalles Bibliográficos
Autores principales: Duran-Moreno, Jose, Kontogeorgakos, Vasileios, Koumarianou, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676724/
https://www.ncbi.nlm.nih.gov/pubmed/31404317
http://dx.doi.org/10.3892/ol.2019.10575
_version_ 1783440821359476736
author Duran-Moreno, Jose
Kontogeorgakos, Vasileios
Koumarianou, Anna
author_facet Duran-Moreno, Jose
Kontogeorgakos, Vasileios
Koumarianou, Anna
author_sort Duran-Moreno, Jose
collection PubMed
description Soft tissue sarcomas (STS) are rare tumors; they do not even equate to 1% of all malignant tumor cases. One-fifth of all STS occur in the upper extremities, where epithelioid sarcoma, synovial sarcoma, clear cell sarcoma and malignant fibrohistiocytoma are the most frequent subtypes. Surgical resection is the cornerstone of treatment. However, accomplishment of optimal oncological and functional results of STS of the upper extremities may represent a challenge for hand surgeons, due to the complex anatomy. In several cases, preoperative therapies are needed to facilitate tumor resection and improve the oncological outcome. Oligometastatic disease may also be a challenging scenario as curative strategies can be applied. Radiotherapy and chemotherapy are commonly used for this purpose albeit with conflicting evidence. Novel drug combinations have also been approved in the metastatic setting, further improving the quality of life and survival of eligible patients. Thus, prior to any approach, every case should be individually discussed in sarcoma centers with specialized multidisciplinary tumor boards. The aim of the present review was to gather the multidisciplinary experiences of the available therapeutic strategies for STS of the upper extremities.
format Online
Article
Text
id pubmed-6676724
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-66767242019-08-09 Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes Duran-Moreno, Jose Kontogeorgakos, Vasileios Koumarianou, Anna Oncol Lett Review Soft tissue sarcomas (STS) are rare tumors; they do not even equate to 1% of all malignant tumor cases. One-fifth of all STS occur in the upper extremities, where epithelioid sarcoma, synovial sarcoma, clear cell sarcoma and malignant fibrohistiocytoma are the most frequent subtypes. Surgical resection is the cornerstone of treatment. However, accomplishment of optimal oncological and functional results of STS of the upper extremities may represent a challenge for hand surgeons, due to the complex anatomy. In several cases, preoperative therapies are needed to facilitate tumor resection and improve the oncological outcome. Oligometastatic disease may also be a challenging scenario as curative strategies can be applied. Radiotherapy and chemotherapy are commonly used for this purpose albeit with conflicting evidence. Novel drug combinations have also been approved in the metastatic setting, further improving the quality of life and survival of eligible patients. Thus, prior to any approach, every case should be individually discussed in sarcoma centers with specialized multidisciplinary tumor boards. The aim of the present review was to gather the multidisciplinary experiences of the available therapeutic strategies for STS of the upper extremities. D.A. Spandidos 2019-09 2019-07-05 /pmc/articles/PMC6676724/ /pubmed/31404317 http://dx.doi.org/10.3892/ol.2019.10575 Text en Copyright: © Duran-Moreno et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Duran-Moreno, Jose
Kontogeorgakos, Vasileios
Koumarianou, Anna
Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes
title Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes
title_full Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes
title_fullStr Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes
title_full_unstemmed Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes
title_short Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes
title_sort soft tissue sarcomas of the upper extremities: maximizing treatment opportunities and outcomes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676724/
https://www.ncbi.nlm.nih.gov/pubmed/31404317
http://dx.doi.org/10.3892/ol.2019.10575
work_keys_str_mv AT duranmorenojose softtissuesarcomasoftheupperextremitiesmaximizingtreatmentopportunitiesandoutcomes
AT kontogeorgakosvasileios softtissuesarcomasoftheupperextremitiesmaximizingtreatmentopportunitiesandoutcomes
AT koumarianouanna softtissuesarcomasoftheupperextremitiesmaximizingtreatmentopportunitiesandoutcomes